Growing potential for umbilical cord stem cells

Exciting development is to develop opportunities for umbilical cord stem cells, in accordance with article, published in November 2009, the opinion of an expert in biological therapy. This article discusses the development of carlecortemcel-l (brand of StemEx), strains of umbilical cord blood stem cells created by encouraging the proliferation of stem cells – without allowing to distinguish.

What does this mean and why is it important?

Although there is much evidence of the healing potential of stem cells extracted from the umbilical cord blood, it was claimed that a limited number of stem cells available from one unit of the banked is not sufficient for the treatment of patients other than children or adults is very small. Creating a method of multiplying these stem cells in their vital State of a pre-differentiated, researchers may potentially face this challenge and widen the application of multiple stem cell treatments.

The results of the phase I study carlecortemcel-l performed at the University of Texas m. d. Anderson Cancer Center reported in the article, suggest that the surcharges these stem cells enlarged umbilical cord is safe – and may be beneficial for adults and adolescents with leukemia and Lymphoma. The continuation phase II/III safety and efficacy studies named Are now registering youth and adults with a high risk of hematologic malignancies in clinical trials in the United States, Italy, Spain, Hungary and Israel. Gamida cell and Teva Pharmaceuticals, co-developers StemEx, predict the product officially reaching cabinets 2011.

Be the first to like this post.Tags: stem cells

This entry was posted on 15 October 2009 at 12: 00 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us

Still the potential Prochymal?

Disappointing is the news today that Prochymal, Osirus Therapeutics mesenchymal stem cells (MSC) therapy, failed in late stage clinical trials in acute Graft-versus-host disease (GvHD). GvHD is a serious difficulty that occurs in some people who received bone marrow from a donor. If the tests were successful, would probably be the first commercial product Prochymal stem cells, approved by the FDA.

However, there are still grounds for hope. First, in one of the trials of GvHD patients with GvHD affecting their liver or gastrointestinal tract, who did not respond to steroid treatment appeared to benefit from Prochymal, although results are still preliminary. In addition, Prochymal is still currently being tested in human trials for several other indications, including type 1 diabetes, heart attack, chronic obstructive pulmonary disease (COPD). The same kind of stem cells used for Prochymal as MSCs – are also in the dental pulp, currently extracted, privately held for families through our national laboratory of the dental pulp. We and many others will continue to track the news and hope for the best as possible stem cell treatment is tested in these areas.

Be the first to like this post.Tags: MSCs, NDPL

This entry was posted on September 9, 2009 at 4: 47 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us

The potential use of Cord Blood treatment of heart and lung disorders

Two new studies of animals, published in the current issue of cell transplantation shows that umbilical cord derived stem cells can have whom the heart and lungs.

In one study, carried out at the Samsung Medical Center in Seoul, the researchers found the therapeutic benefit of having non-cord blood mesenchymal stem cells (MSCs) newborn rats with lung injuries from oxygen. Is still a long way before human use but if perfected, this type of treatment may be the first address disease Acne currently untreatable hyperoxic or chronic (BPD), in infants, premature.

The second study in Germany found that autologous indicate (self-donated) umbilical cord mononuclear cells (UCMNCs) in the heart of improved features in sheep on common defects of cyanotic heart defect, replacement procedures, feasible and safe.

The test takes us to yet another step forward, the enlargement of the list of diseases, which could potentially treat the umbilical cord blood and further strengthen Our belief in the importance of banking cord blood – public or private – to use in the future.

Be the first to like this post.Tags: animals, MSCs, UCMNCs

This entry was posted on December 16, 2009 at 9: 18 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us